Home > Insider Trading > Filing (0001209191-16-145532)

Filing Details

Accession Number:: 0001209191-16-145532
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2016-10-11 13:05:47
Reporting Period:: 2016-10-06

Filing Date:: 2016-10-11
Accepted Time:: 2016-10-11 13:05:47
Original Submission Date:: 2016-10-07
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1337553	Aerie Pharmaceuticals Inc	AERI	Biological Products, (No Disgnostic Substances) (2836)	203109565

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1581754	B. James Tananbaum	3052 Pacific Avenue San Francisco CA 94115	No	No	Yes	No
1594912	Foresite Capital Management Ii, Llc	600 Montgomery Street Suite 4500 San Francisco CA 94111	No	No	Yes	No
1594914	Foresite Capital Fund Ii, L.p.	600 Montgomery Street Suite 4500 San Francisco CA 94111	No	No	Yes	No
1645157	Foresite Capital Management Iii, Llc	600 Montgomery Street Suite 4500 San Francisco CA 94111	No	No	Yes	No
1645158	Foresite Capital Fund Iii, L.p.	600 Montgomery Streeet Suite 4500 San Francisco CA 94111	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2016-10-06	24,813	$40.34	1,647,901	No	4	S	Indirect	See Footnote
Common Stock	Disposition	2016-10-06	25,187	$40.34	1,672,697	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote
No	4	S	Indirect	See Footnote

Footnotes

This transaction was executed in multiple trades at prices ranging from $40.00 to $40.90. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares and the price at which each trade was effected.
The shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner ofFCF II, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacityas managing member of FCM II, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaimsthe existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except tothe extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is thebeneficial owner of these shares for purposes of Section 16 or any other purpose.
The shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have sole voting and dispositive power over these shares. James B. Tananbaum ("Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.